Financial Daily from THE HINDU group of publications
Thursday, Nov 11, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Marketing - New Products & Services


Panacea launches osteoarthritis drug

Our Bureau

New Delhi , Nov. 10

PANACEA Biotec has launched Willgo (Nimesulide 200-mg long acting tablet), an advanced drug delivery system for 24-hour management of pain, inflammation and fever in osteoarthritis and post-surgical conditions.

More Stories on : Announcements | New Products & Services | Pharmaceuticals | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Drug withdrawal may impact generic cos


More products in offing: Biocon
Panacea launches osteoarthritis drug
Biocon launches bio insulin
Lakshadweep gets 9th solar plant from BHEL
Schoeller Tech plant starts operations
`In advertising, get simple, get real'
BPL lenders to move Kerala HC to push through recast package
UB Group looking to bid for SWC liquor biz; Jumbo unmoved
Bunge to merge trading, manufacturing arms
Jubilant to sell 10.4% stake to Citigroup, Henderson — To fund acquisition in the US
Rajasthan Spinning to buy 60% in Jaipur Polyspin
SEBI clears Jindal group co plan to pick SISCOL stake
Phoenix Mecano sets up facility in Pune
Excise exemption for new units in Kutch extended by one year
ITC seeks shareholder nod for change in objects clause of MoA
Gati board clears 1:2 rights offer
Tata Steel targets 15 mt output by 2015
DVC to relook at hydel projects in Bengal, Jharkhand — Appoints CWC to study potential
Software company promoters held for duping depositors in Vizag



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line